CG Oncology, Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 254.70% | 217.84% | -15.23% | 4.09% | 278.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254.70% | 217.84% | -15.23% | 4.09% | 278.41% |
| Cost of Revenue | 47.73% | 60.60% | 70.12% | 76.86% | 91.59% |
| Gross Profit | -44.82% | -59.09% | -71.00% | -77.73% | -90.23% |
| SG&A Expenses | 118.16% | 168.80% | 180.01% | 214.42% | 241.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.23% | 88.60% | 95.72% | 105.26% | 119.66% |
| Operating Income | -66.37% | -87.68% | -96.60% | -106.21% | -118.71% |
| Income Before Tax | -82.87% | -108.09% | -100.11% | -91.07% | -87.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.87% | -108.09% | -100.11% | -91.07% | -87.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.87% | -108.09% | -100.11% | -91.07% | -87.41% |
| EBIT | -66.37% | -87.68% | -96.60% | -106.21% | -118.71% |
| EBITDA | -65.16% | -87.13% | -96.40% | -106.18% | -118.72% |
| EPS Basic | -47.93% | 61.77% | 80.28% | 87.72% | 90.66% |
| Normalized Basic EPS | -47.93% | 51.20% | 74.17% | 83.59% | 87.23% |
| EPS Diluted | -47.93% | 61.77% | 80.28% | 87.72% | 90.66% |
| Normalized Diluted EPS | -47.93% | 51.20% | 74.17% | 83.59% | 87.23% |
| Average Basic Shares Outstanding | 23.73% | 60.30% | 135.03% | 364.80% | 1,385.51% |
| Average Diluted Shares Outstanding | 23.73% | 60.30% | 135.03% | 364.80% | 1,385.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |